Kenvue Inc

Kenvue Inc(KVUE)股票分析

$18.670

+0.683 (+3.66%)收盤時

Loading chart…
最高
18.770
開盤
18.380
成交量加權均價
18.61
成交量
26.36M
市值
35.27B
最低
18.380
成交金額
490.44M
企業價值/稅息折舊攤銷前利潤(TTM)
11.31

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

AI 分析 of Kenvue Inc (KVUE)

買進

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

分析師評級(1)

上檔空間 +1.02%
賣出
0 買進
0 持有
1 賣出
目前: 18.67
最低
17.00
平均
18.86
最高
23.00

UBS

2026-08-11

目標價

$19

中性

Barclays

2026-07-21

目標價

$19

Equal Weight

UBS

2026-07-16

目標價

$20

中性

Citi

2026-04-15

目標價

$19

中性

Barclays

2026-04-14

目標價

$18

Equal Weight

估值指標

Kenvue Inc(KVUE)目前預期本益比為 14.73,5 年平均預期本益比為 17.53。

預期本益比

低估
5 年均值 P/E
17.53
目前P/E
14.73
高估
19.72
低估
15.33

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
12.65
目前EV/EBITDA
11.31
高估
13.80
低估
11.50

預期股價營收比

低估
5 年均值 P/S
2.48
目前P/S
2.14
高估
2.81
低估
2.15

Alphio AI 對 KVUE 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%KVUE

$25.34

情境價格

基

基準

基準 · 50%KVUE

$22.26

情境價格

悲

悲觀

悲觀 · 25%KVUE

$19.40

情境價格

持有 KVUE 的大戶

I

Ingalls & Snyder, LLC

+ 持有KVUE

+11.87%

3個月報酬率

M

Millennium Management LLC

+ 持有KVUE

+8.36%

3個月報酬率

T

Troy Asset Management Ltd

+ 持有KVUE

+6.68%

3個月報酬率

T

Trajan Wealth, L.L.C.

+ 持有KVUE

+6.51%

3個月報酬率

Y

Yacktman Asset Management LP

+ 持有KVUE

+5.83%

3個月報酬率

S

Saturna Capital Corporation

+ 持有KVUE

+5.39%

3個月報酬率

KVUE 常見問題 —— 由 Alphio AI 解答

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易